MASAC Recommendation for Ongoing CDC Surveillance for CJD
View printer-friendly version in PDF format >>
The following recommendation was approved by the Medical and Scientific Advisory Council (MASAC) on March 21, 2009, and adopted by the NHF Board of Directors on June 6, 2009.
Pursuant to a currently unsubstantiated report of possible classic CJD related to the recent death of a person with hemophilia who developed dementia, and in conjunction with recommendations 1 and 2 in the MASAC Consensus Statement on Plasma Safety, MASAC supports the ongoing activities and the potentially expanded role of the CDC in the surveillance of the bleeding disorders population for prion disease and emerging pathogens as a nationally funded public health initiative of both national and global significance.
This material is provided for your general information only. NHF does not give medical advice or engage in the practice of medicine. NHF under no circumstances recommends particular treatment for specific individuals and in all cases recommends that you consult your physician or local treatment center before pursuing any course of treatment.
Copyright 2009 National Hemophilia Foundation. To facilitate the dissemination of these medical recommendations, reproduction of any material in this publication in whole or in part will be permitted provided: 1) a specific reference to the MASAC recommendation number and title is included and 2) the reproduction is not intended for use in connection with the marketing, sale or promotion of any product or service. NHF reserves the right to make the final determination of compliance with this policy. For questions or to obtain a copy of the most recent recommendations, please contact the NHF Director of Communications at 1-800-42-HANDI or visit the NHF website at www.hemophilia.org.